For a pharmacy, drug manufacturer, outsourcing facility, or other FDA-regulated business, receiving a Warning Letter from the U.S. Food and Drug Administration can have consequences that extend far beyond the letter itself. FDA Warning Letters are publicly available. Customers, healthcare providers, business partners, investors, state regulators, and others may learn of the allegations. The resulting reputational and economic consequences can be substantial even when the recipient disputes FDA’s conclusions. Yet challenging an FDA Warning Letter in federal court has historically presented a significant obstacle: FDA generally takes the position that a Warning Letter is not “final agency action” subject to judicial review under the Administrative Procedure Act (“APA”). A recent decision from the United States District Court for the Southern District of Florida, however, demonstrates that the analysis does not necessarily end there. In Hybrid Pharma LLC v. Food and Drug Administration, Case No. 24-62413-CIV-DAMIAN (S.D. Fla.), the Court denied FDA’s motion to dismiss an APA action arising from FDA Warning Letters issued to a Florida outsourcing facility. The decision provides an important example of circumstances in which an FDA-regulated business may be able to obtain judicial review even though the dispute originated with Warning Letters. Fischer Law represented Hybrid Pharma in obtaining the ruling discussed in this article.
The Administrative Procedure Act generally permits a person adversely affected by federal agency action to obtain judicial review when the challenged action constitutes “final agency action.” That requirement has historically created difficulty for companies seeking immediate judicial review of FDA Warning Letters. FDA Warning Letters typically communicate the agency’s position that it believes a regulated entity has violated federal law and request corrective action. But Courts have often treated Warning Letters as advisory or preliminary enforcement communications rather than final agency decisions that independently determine legal rights or obligations. As a result, simply filing suit immediately after receiving a Warning Letter may encounter a threshold argument from FDA that there is no final agency action for a federal court to review. That was one of the central issues presented in Hybrid Pharma.
Hybrid Pharma LLC operates an FDA-registered outsourcing facility under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA issued Warning Letters to Hybrid Pharma following inspections of its facility. Hybrid Pharma disputed FDA’s actions and contended that the Warning Letters had significant consequences for its business and reputation. Among other things, Hybrid alleged substantial business and revenue losses associated with the Warning Letters. The dispute ultimately presented: If a Warning Letter itself is not ordinarily considered final agency action, is there another circumstance in which FDA’s position concerning that Warning Letter becomes sufficiently final to permit judicial review?
Rather than treating the Warning Letters themselves as the only potentially reviewable agency action, Hybrid Pharma sought formal agency review. To accomplish this, Hybrid submitted a Citizen Petition to FDA requesting that the agency rescind the Warning Letters. FDA subsequently denied that request. Hybrid Pharma then sought judicial review under the Administrative Procedure Act. That distinction became critical when FDA moved to dismiss the lawsuit.
The FDA argued that Hybrid’s lawsuit should be dismissed because Warning Letters do not constitute final agency action. According to FDA, Hybrid could not transform a nonfinal Warning Letter into reviewable agency action merely by filing a Citizen Petition and obtaining a response from the agency. FDA also argued that although the Complaint challenged the Citizen Petition decision, Hybrid’s substantive objections were ultimately directed toward the underlying Warning Letters. In other words, FDA urged the court to look past the Citizen Petition denial and characterize the lawsuit as an impermissible attempt to obtain judicial review of Warning Letters. The court ultimately rejected that argument at the motion-to-dismiss stage.
On January 29, 2026, United States District Judge Melissa Damian denied FDA’s Motion to Dismiss Hybrid Pharma’s Amended Complaint. The distinction between the Warning Letters and FDA’s subsequent decision on the Citizen Petition was important. Hybrid was not relying solely upon the issuance of the Warning Letters as the final agency action. It challenged FDA’s denial of the Citizen Petition requesting rescission of those letters. The court determined that Hybrid had sufficiently alleged a cognizable APA claim based on FDA’s denial of the Citizen Petition. As a result, FDA’s argument that the case necessarily failed because Warning Letters themselves are not final agency action did not warrant dismissal.
The legal characterization of a Warning Letter as nonfinal does not mean that the letter has no practical effect. FDA publishes Warning Letters on its website. Once published, a Warning Letter can be discovered by customers, physicians, hospitals, business partners, competitors, investors, state regulators, and others. For a pharmacy, outsourcing facility, manufacturer, medical-device company, or other FDA-regulated entity, the effects may include lost business opportunities, damaged commercial relationships, increased regulatory scrutiny, reputational harm, or concerns from existing and prospective customers. Those consequences can arise long before FDA initiates a traditional enforcement proceeding. Hybrid Pharma alleged precisely this type of real-world harm. The question for a regulated entity may therefore become not merely whether it disagrees with FDA, but what options are available when the agency’s publicly stated position is causing ongoing harm.
The FDA performs an important regulatory function in protecting public health and ensuring compliance with federal law. But the FDA, like other federal agencies, is subject to the APA. The APA provides a mechanism for judicial review of qualifying final agency actions, including circumstances in which agency action is alleged to be arbitrary, capricious, an abuse of discretion, or otherwise contrary to law. The challenge has often been determining when a dispute involving an FDA Warning Letter becomes sufficiently final for a federal court to review it. Hybrid Pharma provides an important recent decision addressing that issue. While the decision does not make Warning Letters themselves universally reviewable, it demonstrates that regulated entities should not necessarily assume that they have no avenue for judicial review merely because their dispute began with an FDA Warning Letter. Businesses facing FDA Warning Letters or other federal regulatory actions should carefully evaluate both the substantive allegations and the procedural options available for challenging agency action.
Fischer Law represents pharmacies, healthcare businesses, manufacturers, and other regulated entities in administrative and federal litigation involving government agencies. Businesses facing significant consequences from FDA regulatory action may contact Fischer Law to discuss their circumstances and available options.
This article is for informational purposes only and does not constitute legal advice. The availability of judicial review depends upon the specific agency action, procedural history, applicable law, and facts of each matter. The court’s denial of the motion to dismiss in Hybrid Pharma did not constitute a final adjudication of the merits of Hybrid Pharma’s claims.